Forte Posts $69.4M Net Loss, $(4.71) EPS in 10-K; Zero Revenue Confirmed
FBRX has more than doubled off its 52-week low of $4.9.
Summary
Forte Biosciences reported its annual 10-K, disclosing a net loss of $69.4 million and a loss per share of $(4.71), with no revenue for the year. These results underscore the substantial cash burn for the pre-commercial biotech, which is significant relative to its market capitalization. While zero revenue is anticipated at this stage, the magnitude of the loss is critical for evaluating the company's financial health and potential future financing needs. The company continues to invest heavily in R&D and clinical development for its lead candidate FB102, with Phase 2 celiac data expected in 2026. Investors will closely monitor the burn rate and the company's ability to maintain its operating runway.
At the time of this announcement, FBRX was trading at $25.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $324.4M. The 52-week trading range was $4.90 to $35.62. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.